The introduction of AMT-143 to the market will offer significant benefits to patients, clinicians, and the wider healthcare community seeking alternatives to addictive medications
AMT-143 (AmacaGel) is an innovative, long-acting, non-opioid anesthetic designed for post-operative pain management. Utilizing AmacaThera's advanced, tunable hydrogel drug delivery platform, AMT-143 delivers a sustained, localized release of ropivacaine directly to the surgical site.
This approach enables effective pain relief without the need to change established surgical practices. AMT-143 is administered via local injection with a pre-filled syringe during surgery. The formulation is specifically optimized to maintain pain control throughout the critical post-operative period, supporting patient comfort and facilitating a smoother recovery.
AMT-143 has undergone clinical evaluation in a Phase 1 trial, demonstrating a sustained release of ropivacaine for up to 14 days. The program is now progressing towards Phase 2 clinical development in partnership with Pacira BioSciences, with the next phase anticipated to begin in 2026.
The introduction of AMT-143 to the market will offer significant benefits to patients, clinicians, and the wider healthcare community seeking alternatives to addictive medications
AMT-143 (AmacaGel) is an innovative, long-acting, non-opioid anesthetic designed for post-operative pain management. Utilizing AmacaThera's advanced, tunable hydrogel drug delivery platform, AMT-143 delivers a sustained, localized release of ropivacaine directly to the surgical site.
This approach enables effective pain relief without the need to change established surgical practices. AMT-143 is administered via local injection with a pre-filled syringe during surgery. The formulation is specifically optimized to maintain pain control throughout the critical post-operative period, supporting patient comfort and facilitating a smoother recovery.
AMT-143 has undergone clinical evaluation in a Phase 1 trial, demonstrating a sustained release of ropivacaine for up to 14 days. The program is now progressing towards Phase 2 clinical development in partnership with Pacira BioSciences, with the next phase anticipated to begin in 2026.
Why 48 hours is a magic number for pain relief
During the development of AMT-143, we engaged extensively with numerous surgeons to gain insights into their clinical routines and to better understand patient experiences following surgery. Surgeons consistently highlighted that patients typically endure the most intense pain during the initial post-operative period. By offering an opioid-free pain management solution at this critical juncture, AMT-143 has the potential to not only improve patient comfort but also significantly reduce the risk of opioid dependency, thereby supporting improved surgical outcomes.
To address this clinical need, AMT-143 has been carefully engineered to provide sustained release of its analgesic agent over a targeted three-day period. Preclinical evaluations indicate that, as the hydrogel formulation gradually acclimatizes to body temperature, the encapsulated drug is steadily released and absorbed, ensuring prolonged and effective pain relief throughout the most challenging phase of recovery.
Each year, 51 million Americans have inpatient surgery, with opioids still widely used for acute post-operative pain relief
Each year, around 51 million Americans undergo inpatient surgery, with opioids remaining the predominant choice for managing acute post-operative pain. The financial burden associated with prescription opioid overdoses, abuse, and dependency surpasses $78.5 billion annually, primarily due to healthcare expenses, substance abuse treatment, and lost productivity.
AMT-143 is uniquely positioned to bridge this critical gap in pain management. At present, the greatest challenge in this market is the lack of a single-dose analgesic that can reliably provide more than 48 hours of effective post-surgical pain relief.